TERT and neoplasm: The subcutaneous injection of the TERT (572Y) peptide followed by the subcutaneous administration of the TERT (572) peptide was aimed to elicit a specific and possibly optimal cytotoxic T-cell (CTL) response against hTERT-expressing tumor cells [95].